The economic burden of chronic thromboembolic pulmonary hypertension in Russian Federation.
暂无分享,去创建一个
I. Chazova | S. Nedogoda | T. Martynyuk | Z. Valieva | A. Salasyuk | S. Nakonechnikov | I. Taran | S. Gratsianskaya
[1] Алексей Сергеевич Колбин,et al. Социально-экономическое бремя хронической мигрени в России , 2019 .
[2] Татьяна Николаевна Ермолаева,et al. Сравнительный анализ стоимости лекарственной терапии самых высокозатратных онкологических заболеваний в городе Москве , 2018 .
[3] H. Schäfers,et al. Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany , 2018, Clinical Research in Cardiology.
[4] Z. Jing,et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. , 2017, The Lancet. Respiratory medicine.
[5] P. Dorfmüller,et al. The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension. , 2016, Annals of the American Thoracic Society.
[6] H. Ghofrani,et al. Quality of life in patients with chronic thromboembolic pulmonary hypertension , 2016, European Respiratory Journal.
[7] Алла Распутина. STATE OF THE ART AND PROBLEMS OF ACCOUNTING IN GOVERNMENTAL NON-BUDGETARY FUNDS (AS IN THE CASE OF THE PENSION FUND OF THE RUSSIAN FEDERATION) , 2015 .
[8] V. Joish,et al. Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension. , 2014, American health & drug benefits.
[9] Мартынюк Тамила Витальевна,et al. Легочная гипертензия в России: первые результаты национального регистра , 2014 .
[10] В. И. Игнатьева,et al. Анализ методологических особенностей исследований по изучению социально-экономического бремени заболеваний в РФ в рамках разработки стандартной методики анализа стоимости болезни с целью ее использования в оценке технологий здравоохранения , 2014 .
[11] Chen Wang,et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. , 2013, The New England journal of medicine.
[12] Horst Olschewski,et al. Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[13] J. Barberà,et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry , 2012, European Respiratory Journal.
[14] W. Auger,et al. Chronic thromboembolic pulmonary hypertension. , 2009, Seminars in respiratory and critical care medicine.
[15] A. Torbicki,et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. , 2008, Journal of the American College of Cardiology.
[16] N. Morrell,et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. , 2008, Chest.
[17] P. Corris,et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.